AMAG Financial Facts
License fee and other collaboration revenues: 2MSelling, general and administrative expenses: 14.01M
See Full Income Statement
Total liabilities: 77.02M
Other long-term liabilities: 1.92M
See Full Balance Sheet
Earnings History for AMAG Pharmaceuticals, Inc. (AMAG)
|
Expand Research on AMAG
| Next EPS Date | 5/28/13 *Est. | EPS Growth Rate | +80.5% *Last Qtr. |
|---|---|---|---|
| Average EPS % Beat Rate | +13.7% | Revenue Growth Rate | +41.9% *Last Qtr. |
| Average % Move 1-Wk after EPS | +3.3% |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Estimize EPS/Revs | Gd. | % Since | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 3/1/13 | Q412 | -$0.17 | -$0.07 | -$0.10 | $21.14M | $22.54M | N/A / N/A | = | +32.6% | Details | |
| 11/1/12 | Q312 | -$0.19 | -$0.26 | +$0.07 | $17.7M | $20.43M | N/A / N/A | N/A | +41.7% | Details | |
7/26/12  |
 |
Q212 | $0.15 | -$0.31 | +$0.46 | $31M | $21.29M | N/A / N/A | N/A | +44.3% | Details |
| 3/5/12 |
|
Q411 | -$0.87 | -$1.12 | +$0.25 | $14.9M | $14.72M | N/A / N/A | N/A | +39.9% | Details |
| 11/4/11 |
|
Q311 | -$0.78 | -$1.00 | +$0.22 | $17.6M | $16.22M | N/A / N/A | N/A | +59.6% | Details |
| 7/26/11 |
|
Q211 | -$0.92 | -$1.06 | +$0.14 | $15.4M | $14.8M | N/A / N/A | N/A | +41.2% | Details |
| 5/3/11 |
|
Q111 | -$1.05 | -$1.02 | -$0.03 | $13.4M | $15.25M | N/A / N/A | N/A | +23.3% | Details |
| 2/25/11 |
|
Q410 | -$0.94 | -$1.04 | +$0.10 | $17.2M | $16.76M | N/A / N/A | N/A | +27.3% | Details |
